NeuroSense Therapeutics 뉴스 - NRSN

기업명	주식 심볼	시장	주식 타입
NeuroSense Therapeutics Ltd	NRSN	나스닥	보통주

	가격 변동	가격 변동 %	주식 가격	최근 거래 시간
	-0.09	-6.67%	1.26	07:30:10

개장가	저가	고가	종가	전일 종가
1.37	1.24	1.42	1.26	1.35

시세 정보 더보기 »

최근 뉴스

일자	시간	출처	제목
22/04/2024	21:30	PRNUS	NeuroSense and Genetika+ Initiate Precision Medicine..
18/04/2024	21:30	PRNUS	NeuroSense Presents Positive Data Validating Phase 2b..
12/04/2024	21:30	PRNUS	NeuroSense to Present PARADIGM Data at the American Academy..
11/04/2024	08:16	PRNUS	NeuroSense Announces Pricing of $4.5 Million Registered..
09/04/2024	21:30	PRNUS	NeuroSense Collaborates with Lonza to Identify Exosome-based..
05/04/2024	22:29	PRNUS	NeuroSense Announces Year End 2023 Financial Results and..
22/02/2024	22:25	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/02/2024	22:30	PRNUS	NeuroSense Reports Additional Positive Results from its ALS..
14/02/2024	03:20	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
14/02/2024	00:14	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
07/02/2024	23:38	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/02/2024	23:27	PRNUS	NeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
09/01/2024	22:49	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/01/2024	22:48	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/01/2024	22:45	PRNUS	NeuroSense Recaps Positive 2023 Achievements Including..
28/12/2023	07:03	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
28/12/2023	07:01	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/12/2023	07:00	PRNUS	NeuroSense Announces Receipt of Nasdaq Notice Regarding..
21/12/2023	22:45	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/12/2023	06:30	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
14/12/2023	23:41	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/2023	23:24	PRNUS	NeuroSense Reports New Data: Statistically Significant..
06/12/2023	05:15	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
06/12/2023	05:00	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
05/12/2023	22:01	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/2023	22:00	PRNUS	NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
05/12/2023	14:15	EDGAR2	Form EFFECT - Notice of Effectiveness
05/12/2023	06:01	PRNUS	NeuroSense to Report Phase 2b ALS Topline Primary Safety and..
04/12/2023	20:17	EDGAR2	Form POS AM - Post-Effective amendments for registration..
28/11/2023	23:00	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/2023	22:45	PRNUS	NeuroSense Announces Third Quarter 2023 Financial Results..
22/11/2023	00:36	EDGAR2	Form POS AM - Post-Effective amendments for registration..
13/11/2023	23:28	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/2023	23:20	PRNUS	NeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
09/11/2023	23:00	PRNUS	NeuroSense Therapeutics to Present at Upcoming U.S. and..
06/11/2023	22:35	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/2023	22:30	PRNUS	NeuroSense Completes Dosing of Last Patient in the..
01/11/2023	22:00	PRNUS	NeuroSense Therapeutics to Participate in BIO-Europe Fall
17/10/2023	21:45	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/10/2023	21:30	PRNUS	NeuroSense CEO Provides Q3 2023 Update
04/10/2023	22:12	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/2023	22:10	PRNUS	NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
03/10/2023	00:39	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/09/2023	22:16	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/09/2023	22:05	PRNUS	European Medicines Agency Grants NeuroSense SME Status
19/09/2023	22:15	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/09/2023	22:00	PRNUS	NeuroSense Granted Patents in Europe, Japan, and Israel for..
14/09/2023	22:00	PRNUS	NeuroSense to Participate in Upcoming ALS Conferences:..
12/09/2023	22:20	EDGAR2	Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/09/2023	05:31	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]

이 » 주식의 기사 더보기;

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

NRSN NeuroSense Therapeutics Ltd

최근 뉴스

NRSN 과거 데이터 - 1일

NRSN 과거 데이터 - 1년

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

NeuroSense Therapeutics Ltd (NRSN) 뉴스

NRSN NeuroSense Therapeutics Ltd

최근 뉴스

NRSN 과거 데이터 - 1일

NRSN 과거 데이터 - 1년

최근 히스토리

회사 소개

사업

Popular

앱 받기